Actively Recruiting
Phase 1 Study of Donor-Derived T Cell Therapy to Prevent COVID-19 in Immunocompromised Patients After Stem Cell Transplant
Led by Children's National Research Institute · Updated on 2026-03-12
24
Participants Needed
2
Research Sites
58 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new therapy using coronavirus-specific T cells CST to prevent COVID-19 infection in patients who have weakened immune systems after hematopoietic stem cell transplantation HSCT. This phase I open-label trial focuses on evaluating the safety of donor-derived CSTs in adults and children who are at risk of SARS-CoV-2 infection following HSCT. The study aims to test different doses and monitor antiviral effects while ensuring participant safety. Participants will receive one infusion of CSTs derived from their HSCT donor between 28 days and less than 4 months after their transplant. The trial includes separate groups for adults aged 18 to under 80, adolescents aged 12 to under 18, and children aged 2 to under 12, with dose escalation starting in adults and then moving to pediatric groups after safety reviews. Three dose levels will be tested with staggered infusions and close monitoring. During the study, participants will have frequent follow-up visits for up to one year after the CST infusion. These visits include medical exams, blood tests, and collection of research samples to monitor safety, potential side effects, and immune responses. Researchers will assess serious infusion-related adverse events, graft versus host disease, inflammatory syndromes, and antiviral immune activity as primary and secondary outcomes.
CONDITIONS
Brief Title
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
Research Team
S
Susan Conway, MD
F
Fahmida Hoq, MBBS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here